180 Wealth Advisors LLC Makes New $209,000 Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

180 Wealth Advisors LLC bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, HoldingsChannel reports. The firm bought 629 shares of the company’s stock, valued at approximately $209,000.

Several other hedge funds also recently bought and sold shares of the company. Wealth Alliance raised its holdings in Medpace by 2.9% in the second quarter. Wealth Alliance now owns 970 shares of the company’s stock worth $399,000 after purchasing an additional 27 shares during the period. Centaurus Financial Inc. raised its holdings in Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after purchasing an additional 29 shares during the period. Lindenwold Advisors INC raised its holdings in Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock worth $676,000 after purchasing an additional 32 shares during the period. M&T Bank Corp raised its holdings in Medpace by 1.2% in the third quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock worth $1,068,000 after purchasing an additional 37 shares during the period. Finally, Nations Financial Group Inc. IA ADV raised its holdings in Medpace by 1.7% in the third quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company’s stock worth $793,000 after purchasing an additional 39 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on MEDP. Robert W. Baird raised their price objective on shares of Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a report on Monday, November 25th. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $415.00 to $345.00 in a report on Wednesday, September 25th. Baird R W lowered shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. TD Cowen dropped their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Finally, Redburn Atlantic began coverage on shares of Medpace in a report on Monday, October 14th. They set a “buy” rating and a $404.00 price objective on the stock. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $380.56.

Medpace Price Performance

Shares of MEDP opened at $335.23 on Thursday. The firm has a 50-day moving average of $341.36 and a 200-day moving average of $358.26. Medpace Holdings, Inc. has a one year low of $277.72 and a one year high of $459.77. The company has a market cap of $10.42 billion, a PE ratio of 29.35, a price-to-earnings-growth ratio of 1.91 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping the consensus estimate of $2.77 by $0.24. The business had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Medpace’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.22 EPS. Analysts expect that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.